Fate Therapeutics (FATE) Accumulated Expenses (2012 - 2026)

Fate Therapeutics has reported Accumulated Expenses for 15 years, with the latest figure at $13.6 million in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses rose 163.0% year-over-year to $13.6 million; the trailing twelve-month figure through Mar 2026 stood at $13.6 million (up 163.0% YoY), and the FY2025 full-year result was $9.1 million, down 57.45% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $13.6 million, up from $9.1 million in the prior quarter.
• The five-year high for Accumulated Expenses was $53.9 million in Q4 2022, with the low at $5.2 million in Q1 2025.
• Historically, Accumulated Expenses has averaged $18.2 million across 5 years, with a median of $16.6 million in 2022.
• Annual changes were most pronounced in 2022 — Accumulated Expenses soared 319.32% — and 2023, when it slumped 82.81%.
• Fate Therapeutics' Accumulated Expenses stood at $53.9 million in 2022, then slumped by 80.41% to $10.6 million in 2023, then surged by 102.1% to $21.3 million in 2024, then slumped by 57.45% to $9.1 million in 2025, then jumped by 50.19% to $13.6 million in 2026.
• The last three Accumulated Expenses figures came in at $13.6 million (Q1 2026), $9.1 million (Q4 2025), and $7.4 million (Q3 2025), per Business Quant data.